X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Pfizer And Touchlight Enter Into A Patent Collaboration

Content Team by Content Team
8th July 2022
in Manufacturing, Middle East and South Asia, News
Pfizer And Touchlight Enter Into A Patent Collaboration

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Pfizer and another pharmaceutical major, Touchlight, have come to a deal on a significant non-exclusive patent licence. Touchlight is a firm that focuses on enzymatic DNA manufacturing to further enhance genetic therapies.

As a result of the licencing arrangement, Pfizer will now have the rights to Touchlight’s portfolio of enzymatic doggybone DNA (dbDNA) patents for international use. The company plans to use the product largely in the production and commercialization of their messenger RNA-based vaccines, and this will be its primary focus. On the other hand, it will also be utilised in the expansive variety of medicines and gene therapies that it offers. The pharma giant will make an initial payment to Touchlight as well as compensation for completing certain clinical and commercial milestones and royalties once the company’s product has been brought to market.

A minimum, linear, double-stranded, and structurally closed DNA vector is produced by the patented dbDNA technology developed by Touchlight. This vector is produced by an enzymatic manufacturing method. dbDNA is in a position that is unmatched by any other company to facilitate the speedy, synthetic, and scalable production of guanosine monophosphate (GMP) DNA while maintaining a compact and straightforward footprint.

Additionally, the method is able to produce genes and accommodate sequences that are normally unstable when present as plasmid DNA in E. coli. Examples of such sequences include those that are included in viral vector and mRNA production. It is perfectly suited for the creation of DNA vaccines as well as sophisticated therapeutics, besides mRNA vaccines.

Touchlight was founded by Jonny Ohlson, who now serves as the company’s executive chair. He stated that they are happy to strike this arrangement with Pfizer to licence their mRNA production platform. This collaboration is an example of how their technology has the potential to help enterprises throughout the genetic medicine industry to streamline and expedite the manufacture of DNA through the clinic towards commercialization.

Previous Post

AstraZeneca, GSK Weathered Q2 Storm, But Roche Stock Plunged

Next Post

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Lonza To Construct $518mn Fill-Finish Plant In Switzerland

Lonza To Construct $518mn Fill-Finish Plant In Switzerland

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In